03:00 , Aug 10, 2018 |  BC Innovations  |  Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication. Sarcopenia...
01:53 , Jan 25, 2018 |  BC Innovations  |  Translation in Brief

No TNFα for transplants

A University of Toronto team has shown that inhibiting TNFα enhances the engraftment success of hematopoietic stem cell transplants in mice and plans to test the strategy in the clinic using Enbrel etanercept within a...
21:09 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

TXA127 regulatory update

FDA granted rare pediatric disease designation to TXA127 from Tarix to treat recessive dystrophic epidermolysis bullosa (RDEB). TXA127, a formulation of the angiotensin (1-7) peptide, a MAS receptor agonist, also has Orphan Drug designation for...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Sarconeos: Phase I started

Biophytis began the double-blind, placebo-controlled, dose-escalation, Belgian Phase I SARA-PK trial of Sarconeos. The first part will evaluate single doses of Sarconeos in 32 elder and young healthy volunteers, and the second part will test...
07:00 , Sep 17, 2012 |  BioCentury  |  Product Development

Excited about cycling

New synthesis and screening technologies and the allure of access to previously undruggable targets are driving an explosion of new company formation and deal-making around macrocycles and constrained peptides. While it remains to be seen whether...
01:38 , Feb 22, 2012 |  BC Extra  |  Company News

Lanthio, Tarix in pulmonary deal

Lanthio Pharma B.V. (Groningen, the Netherlands) granted Tarix Pharmaceuticals Ltd. (Brookline, Mass.) exclusive, worldwide rights to its lanthionine-Ang(1-7) peptide. According to Lanthio, the preclinical product targets the MAS receptor and is being developed for acute...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Lanthio Pharma, Tarix deal

Lanthio granted Tarix exclusive, worldwide rights to its lanthionine-Ang(1-7) peptide. According to Lanthio, the preclinical product targets the MAS receptor and is being developed for acute lung injury and related indications. Lanthio is...
08:00 , Feb 20, 2012 |  BioCentury  |  Emerging Company Profile

Lanthio: Bacterial stabilization

A major drawback of therapeutic peptides is their rapid degradation and loss of function in the body. Lanthio Pharma B.V. has developed its bacteria-based peptide stabilization technology to provide libraries of peptides that are resistant...